Chemotherapy advances in head and neck oncology

William Liggett, Arlene A. Forastiere

Research output: Contribution to journalArticlepeer-review


Chemotherapy has an expanding role in the treatment of squamous cell carcinoma of the head and neck. Patients with recurrent or meta‐static disease that have a good performance status should receive combination therapy with cisplatin and 5‐fluorouracil or enter investi‐gational protocols. Neoadjuvant chemotherapy should be offered to patients with laryngeal carcinoma as an alternative to surgery. Adjuvant chemotherapy should be considered in patients with an increased risk for relapse. Combined chemoradiotherapy may improve locore‐gional control and impact on survival. Chemoradiotherapy warrents further investigation through clinical trials and should be considered for patients at high risk for relapse. As the biology of these tumors becomes better defined, so too will our ability to define subsets of patients who may benefit from combined modality treatment. © 1995 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)265-271
Number of pages7
JournalSeminars in surgical oncology
Issue number3
StatePublished - Jan 1 1995


  • adjuvant chemotherapy
  • chemotherapy
  • head and neck cancer
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy advances in head and neck oncology'. Together they form a unique fingerprint.

Cite this